PIPAC Pharmacologic and Clinical Data
Delia Cortés-Guiral1, Onno Kranenburg2,3, Olivia Sgarbura4
1IVOQA (Viamed Advanced Surgical Oncology Institute), Hospital Viamed Santa Elena, Madrid, Spain.
Journal of Surgical Oncology
|September 24, 2024
Summary
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) offers a novel approach for peritoneal malignancies, improving treatment efficacy. Promising results in various cancers suggest PIPAC may change palliative care options for many patients.
Area of Science:
- Oncology
- Surgical Oncology
- Chemotherapy Delivery Systems
Background:
- Systemic therapies often show limited efficacy in treating peritoneal malignancies.
- Peritoneal carcinomatosis presents a significant challenge in cancer treatment.
- Novel drug delivery methods are needed to improve treatment response.
Purpose of the Study:
- To introduce Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as an innovative treatment modality.
- To evaluate the potential of PIPAC in managing peritoneal malignancies.
- To highlight the changing treatment landscape for patients with peritoneal metastasis.
Main Methods:
- PIPAC involves delivering chemotherapy as an aerosol under pressure into the peritoneal cavity.
- This method aims to enhance drug penetration and distribution within the peritoneum.
- Clinical application across various peritoneal tumors is being explored.
Main Results:
- PIPAC has demonstrated promising results in patients with mesothelioma peritonei.
- Positive outcomes have been observed in peritoneal metastasis from gastric, ovarian, colorectal, pancreatic, and hepatobiliary cancers.
- These results indicate a potential improvement over traditional palliative treatments.
Conclusions:
- PIPAC is an innovative intraperitoneal chemotherapy delivery system.
- It shows promise for improving treatment response in peritoneal malignancies.
- Ongoing clinical trials are crucial to further define the benefits of PIPAC.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
159
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
159
01:19Pharmacovigilance
786
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
786
01:28Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
01:21Drugs for Treatment of Constipation-Predominant IBS
143
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
143
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
496
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
496
01:12Analysis of Population Pharmacokinetic Data
239
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
239